Healthcare

We create and invest in leading companies in therapeutics, medtech, and health IT & services.

20

Twenty products and drugs approved

With another 11 drugs in phase 3. Typically, only 1 in 5,000 drugs makes it from idea to market.

18

Eighteen companies created from scratch

If we can't find a company solving an important problem, we create one ourselves - just like we did with Innovent, Denali, and Beam to name a few.

$1.8B

Nearly two billion dollars over seven funds

Without the pressure of fundraising from outside investors, we're privileged to champion companies that help heal the world.

Category

Region

Status

  • Nascent biotech company harnessing emerging science on the importance of Glia in brain disease.

  • ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. Specifically, ABK holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the growing field of embolotherapy within the Interventional Radiology/Interventional Oncology medical disciplines. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique, breakthrough embolotherapy products. Learn more at www.abkmedical.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Halifax, Nova Scotia

    • Year Invested

      2019

    • Team

      Ketan Patel, M.D.

  • Acacia Pharma (EURONEXT:ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Learn more at www.acaciapharma.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, United Kingdom

    • Year Invested

      2013

    • Team

      Alex Pasteur, Ph.D.

  • Accuri Cytometers was a life sciences tools company that democratized flow cytometry for medical and pharmaceutical research. Accuri Cytometers was acquired by Becton Dickinson.

  • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. Learn more at www.aclaristx.com.

  • Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

  • Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Learn more at www.adaptimmune.com.

  • Affinia Therapeutics is a gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases. Learn more at www.affiniatx.com.

  • Amphora Medical was a medical device technology company developing minimally invasive products to restore the quality of life of people suffering from Overactive Bladder Syndrome.

  • Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade. Learn more at www.apellis.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Crestwood, KY

    • Year Invested

      2017

    • Team

      Stephen Knight, M.D.

  • Artemis Health helps companies utilize their data to optimize their benefits programs while minimizing their spend. The Artemis Platform provides customers with actionable data on their benefits programs, opportunities and gaps, and easy-to-use tools to help them make great decisions. Learn more at https://www.artemishealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Salt Lake City, UT

    • Year Invested

      2017

    • Team

      Jon Lim

  • Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions
    to patients suffering from CNS disorders. Arvelle is responsible for the development and
    commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Learn more at www.arvelletx.com.

  • Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Learn more at www.avalynpharma.com.

  • Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease. Learn more at www.aviditybiosciences.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      San Diego, CA

    • Year Invested

      2014

  • b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide. Learn more at http://www.b1.co/.

  • Zhejiang Bang Er Medical Investment Management Co., Ltd. is a leading private medical service provider that operates several private hospitals specializing in orthopedic care and related services in China. Learn more at www.zjbanger.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Zhejiang, China

    • Year Invested

      2015

    • Team

      Chong Xu, Ph.D.

  • Beam Therapeutics (NASDAQ: BEAM) is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time. Learn more at www.beamtx.com.

  • Benchling is the leader in cloud-based informatics for life science R&D. The company offers a unified R&D platform purpose-built for biologics, including solutions for Lab Notebook, Molecular Biology, Bioregistration, Sample Tracking, Requests and Workflow Management. Benchling is used by over 100,000 scientists globally throughout multinational pharmaceutical corporations, emerging biotechnology companies, and major research institutions. Learn more at https://benchling.com/.

    • Category

      • Enterprise IT
      • Health IT/Services

    • Status

      • Private

    • Location

      San Francisco, CA

    • Year Invested

      2018

    • Team

      Shervin Ghaemmaghami, Jon Lim

  • BenchSci exponentially increases the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Learn more at www.benchsci.com.

  • Better Life Medical is a fully-integrated hearing aid manufacturer developing and commercializing novel digital programmable hearing aid solutions for the Chinese market. Learn more at www.goblm.com.cn/.

  • Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.

     

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Cambridge, MA

    • Year Invested

      2007

    • Team

      Stephen Knight, M.D.

  • BioConnect Systems was a medical device company that developed a CE-Marked product for improving dialysis access  surgery. Learn more at www.bioconnectsystems.com.

  • BioPalette is a life science start up formed out of Kobe University developing base editing technology for a range of applications. Learn more at www.biopalette.co.jp.

  • BioRegen Biomedical is a fully integrated medical product company based on a proprietary technology platform. BioRegen is developing and commercializing high quality hyaluronic acid (“HA”) based products for the Chinese market. Learn more at www.bioregenmed.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      China

    • Year Invested

      2010

    • Team

      Chong Xu, Ph.D.

  • Blueprint Medicines (NASDAQ: BPMC) is a precision therapy company striving to improve human health. Learn more at www.blueprintmedicines.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2012

    • Team

      Stephen Knight, M.D.

  • Buoy is an online symptom and cure checker that uses an intelligent algorithm backed by medical data to diagnose patients. Learn more at www.buoyhealth.com.

  • Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited. Learn more at www.caplinpoint.net.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Chennai, Tamil Nadu, India

    • Year Invested

      2019

    • Team

      Ketan Patel, M.D.

  • CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.

  • CareStack™ is a cloud based platform that combines dental practice management, patient engagement and data analytics. Learn more at www.carestack.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Orlando, Florida and Kerela, India

    • Year Invested

      2018

    • Team

      Carl Byers, Brett Cook

  • Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies. Learn more at www.cariboubio.com.

  • Centivo is a new type of self-funded health plan built specifically for employers and their employees and families.  The Company targets zero healthcare trend and improved healthcare outcomes by rewarding members and providers for smart choices and actions while delivering an exceptional member experience. Centivo serves as a health plan or third-party administrator (TPA) for employers and partners closely with local health plans and TPAs to enhance their offerings. Learn more at www.centivo.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      New York, NY

    • Year Invested

      2018

    • Team

      Jon Lim

  • Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Learn more at www.checkmatepharma.com.

  • Cipla Health focuses on developing and commercializing products in the consumer healthcare and over-the-counter categories. Learn more at www.ciplahealth.in.

  • Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide. Learn more at www.coherus.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Redwood City, CA

    • Year Invested

      2014

  • Compass is comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets. Learn more at www.compasstherapeutics.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Cambridge, MA

    • Year Invested

      2015

    • Team

      Stephen Knight, M.D.

  • CORE provides high-end diagnostics services for disease stratification and therapy selection. Learn more at www.corediagnostics.in.

  • Curegenix is a Chinese leader in discovery and development of novel drugs in stem cell related diseases. Learn more at www.curegenix.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      China

    • Year Invested

      2016

    • Team

      Kevin Chu

  • Cygnus Hospitals is an asset-light chain of 10 hospitals based in North India, focusing on select higher-secondary and tertiary-care specialties. Learn more at www.cygnushospitals.com.

  • Cytek Biosciences Inc. is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capabilities. Learn more at www.cytekbio.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      China

    • Year Invested

      2015

    • Team

      Kevin Chu

  • Denali Therapeutics (NASDAQ:DNLI) is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. Learn more at www.denalitherapeutics.com.

  • Devoted Health is building a tech-enabled health insurance and clinical services solution focused on dramatically improving health care for seniors in the U.S. Learn more at www.devoted.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Waltham, MA

    • Year Invested

      2017

    • Team

      Carl Byers

  • Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ:RARE).

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Cambridge, MA

    • Year Invested

      2013

    • Team

      Thomas Beck, M.D.

  • Embark Veterinary, Inc. launched in 2015 with a mission to end preventable disease in dogs. An Embark Dog DNA Test enables pet owners to learn about their dog’s breed, ancestry, health, and what diseases may be in the future – all with a simple cheek swab. By using 100 times more genetic information than any other test available, the company offers the most accurate results on the market. Embark was started by two brothers, Adam and Ryan Boyko, who have a passion for scientific research and a lifelong love of dogs. Embark is an official research partner with Cornell University College of Veterinary Medicine.  Learn more at www.embarkvet.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Boston, MA

    • Year Invested

      2019

    • Team

      Carl Byers

  • Eyebright Medical Technology Co., Ltd. is an emerging leader in the ophthalmologic device market in China. Learn more at www.ebmedical.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Beijing, China

    • Year Invested

      2015

    • Team

      Chong Xu, Ph.D.

  • Eywa is a global generic pharmaceutical company engaged in research and development, manufacture, marketing, sale, and distribution of generic finished dosage formulations. Learn more at www.eywapharma.com.

  • Farapulse is a medical device company developing a novel approach to treating a range of arrhythmias using pulsed electric field. Learn more at www.farapulse.com.

  • Founded by experienced physician innovators and technology entrepreneurs, Firefly marries sophisticated technology with a thoughtful care team experience for continuous, intelligent care that changes behavior and drives value. The platform enables people to make smart choices about their health, while allowing clinicians to provide unparalleled, consistent and proactive care. Learn more at firefly.health.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Wellesley, MA

    • Year Invested

      2019

    • Team

      Carl Byers, Brooke Hammer

  • FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.

  • Genomics plc’s vision is to use genomic insights to transform the drug discovery industry by getting better drugs developed more quickly and targeted at the right group of patients. Learn more at https://www.genomicsplc.com

  • Gu Sheng Tang (“GST”) is a Guangzhou, China-based healthcare services provider that operates a chain of private clinics specializing in traditional Chinese medicine. Learn more at www.gstzy.cn.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Guangzhou, China

    • Year Invested

      2015

    • Team

      Kevin Chu

  • Health Technology is a mobile platform for hospitals that connects patients, optimizes the patient’s hospital visit experience, and streamlines administrator workflow. Learn more at www.gzhc365.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Guangzhou, China

    • Year Invested

      2016

    • Team

      Chong Xu, Ph.D.

  • Hile (603718.SS) is a leading animal vaccine manufacturer that specializes in sales, marketing and commercialization of animal vaccine products in China. Learn more at www.hile-bio.com/.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Shanghai, China

    • Year Invested

      2010

  • Huan Qui Li Kang Technology Co., Ltd. (“HQ”) is an early stage hemostatic product manufacturer in China.

  • Hua Medicine (2552.KHK) is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Learn more at www.huamedicine.com.

  • Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.  Ikano was acquired by UCB.

  • Indalo Therapeutics, a preclinical biotechnology company dedicated to developing therapies for fibrosis, is formed with an experienced team, strong IP, and robust portfolio of drug candidates. Learn more at www.indalotherapeutics.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      St. Louis, MO

    • Year Invested

      2017

    • Team

      Nihal Sinha, M.D.

  • Innovent Biologics (1801.SS) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Learn more at www.innoventbio.com.

  • Insilico specializes in artificial intelligence for drug discovery, biomarker development and aging research. Learn more at www.insilico.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Hong Kong

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • Iora Health is building a different kind of health system to deliver high impact, relationship based care. Learn more at www.iorahealth.com.

  • Ironwood Pharmaceuticals (NASDAQ:IRWD) developed  linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation. Learn more at www.ironwoodpharma.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2002

    • Team

      Stephen Knight, M.D.

  • Ivenix is dedicated to eliminating infusion-related patient harm, uniquely positioned at the crossroads of healthcare IT and infusion delivery. Learn more at www.ivenix.com.

  • Kyruus uses the science of data-driven clinical matching to ensure that patients are being matched to the right provider and enabling healthcare systems to coordinate care delivery across their provider networks. Learn more at www.kyruus.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Boston, MA

    • Year Invested

      2012

    • Team

      Jon Lim, Carl Byers

  • Laurus Labs (NSE:LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad. Learn more at www.lauruslabs.com.

  • Liazon is a provider of web-based private benefits exchanges to small and medium-sized businesses. Liazon was acquired by Towers Watson in 2013. Learn more at www.liazon.com.

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      Buffalo, NY

    • Year Invested

      2012

    • Team

      Jon Lim

  • LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Bozeman, MT

    • Year Invested

      2008

    • Team

      Stephen Knight, M.D.

  • Lumere (formerly Procured Health) is an organization comprised of clinicians, researchers, pharmacists and strategic thought leaders focused on helping health systems eliminate unwarranted clinical variation and cut unnecessary costs—specifically related to device and drug selection and utilization. This company was acquired by Global Healthcare Exchange (GHX) in 2020.

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      Chicago, IL

    • Year Invested

      2012

    • Team

      Jon Lim

  • LunaDNA is the first health and genomic data platform owned by its community of personal health information donors. LunaDNA empowers individuals to share their health data for medical research and the greater good of the community. As community owners in the LunaDNA platform, members share in the value created from health discoveries and medical breakthroughs. LunaDNA was created by the privately-owned Public Benefit Corporation, LunaPBC, founded in 2017 and headquartered in La Jolla, California. The LunaPBC team, investors, and advisors are renowned in the patient-advocacy, health, and science fields, including several former chief executives of Illumina, industry academics, and financial executives. Learn more at www.lunadna.com.

  • Madaket automates the manual, error-prone process of enrollment for healthcare providers and payers. The result is less paperwork and faster payments for hospitals, health systems, and private practices. Learn more at www.madakethealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Cambridge, MA

  • MDDF is a medical device company focused on the manufacturing, development, and commercialization of high quality, affordably priced cardiovascular and general surgery medical devices for the Chinese market.

     

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Beijing, China

    • Year Invested

      2011

    • Team

      Kevin Chu

  • Medbanks is building a data service platform for oncologists and cancer care centers in China. Learn more at www.medbanks.cn.

  • Medwell Ventures Private Unlimited (“Medwell”) is an operator of specialty home healthcare services in India. Learn more at www.medwellventures.com.

  • Menlo Therapeutics Inc. (NASDAQ: MNLO) is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Learn more at www.menlotherapeutics.com.

  • Mersana Therapeutics (NASDAQ:MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines. Learn more at www.mersana.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2005

    • Team

      Thomas Beck, M.D.

  • Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Oakland, CA

    • Year Invested

      2018

    • Team

      Kevin Chu

  • Nanos Medical develops, manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others. Learn more at www.nanosmedical.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Shanghai, China

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. Learn more at www.nebula.org.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      San Francisco, CA and Boston, MA

    • Year Invested

      2018

    • Team

      Carl Byers, Hannah Arnold

  • NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.

  • NFlection Therapeutics is a biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders. Learn more at www.nflectionrx.com.

  • Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including pain, cough and itch.  Learn more at www.nociontx.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Cambridge, MA

    • Year Invested

      2019

    • Team

      Thomas Beck, M.D.

  • NodThera is a biotech engaged in innate immune/inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. Learn more at www.nodthera.com

  • Notable is an AI powered healthcare company that puts appointments on autopilot. By analyzing historical patterns of practice, Notable proactively automates away hundreds of manual repetitive tasks like adding diagnoses, orders, templates, billing codes, and more. Learn more at www.notablehealth.com.

  • NovaMed Pharmaceuticals is a revenue-generating specialty pharmaceutical company focused on the commercialization of branded innovative therapies for diseases with high unmet medical need in China, including oncology, urology, and cardiovascular.  NovaMed was acquired by SciClone.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Shanghai, China

    • Year Invested

      2007

  • Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at www.orchard-tx.com.

  • Orient Speech Therapy Limited (“OST”) is a Hong-Kong based healthcare services provider that operates a chain of private speech therapy clinics in China. Learn more at www.dfqy.com.

  • Oviva is a new type of healthcare provider using technology to scale the dietitian workforce to help meet the growing number of patients with diet-related health conditions. Learn more at www.oviva.com/uk/.

  • Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost. Learn more at www.owkin.com.

  • PatientPing is a care coordination platform that reduces the cost of healthcare by seamlessly connecting providers to coordinate patient care. Learn more at www.patientping.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Boston, MA

    • Year Invested

      2015

    • Team

      Jon Lim, Brett Cook

  • PharmEasy is one of India’s largest healthcare delivery platforms. The company helps patients connect with local pharmacy stores and diagnostic centers in order to fulfill their medical needs. Learn more at www.pharmeasy.in.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Mumbai, India

    • Year Invested

      2018

    • Team

      Carl Byers

  • Plasmagen is an Indian biopharma company that specializing exclusively in Plasma Protein Therapy. Learn more at www.plasmagen.in.

  • Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics. Learn more at www.precisionbiosciences.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Durham, NC

    • Year Invested

      2015